Publication Summaries

Building on our previous summary of ‘Blood and Bone’, where we examined how sample sources affect KIT D816V test sensitivity, we now sharpen our focus on test sensitivity, molecular data interpretation and prognostic insights in SM. How do different detection methods align, and what can mutational burden reveal about disease progression? A recent review by Cilloni et al. sheds light on the recommended methods for diagnosis and follow-up.¹

Powerful -omics tools are unlocking new insights in systemic mastocytosis (SM). This summary highlights the latest proteomics data from Iribarren et al., which aim to identify biomarkers that differentiate SM subtypes with varying prognoses. By comparing SM with another myeloproliferative  disorder, the study also identifies SM-specific biomarkers and delves into their cellular origins.¹

Another key tool in the haematological assessment toolkit is testing for KIT D816V. The presence of this somatic mutation in clonal cells is common in SM. However, the question of which tissue type should be tested for KIT D816V to yield the highest sensitivity result is only just now being answered. Navarro-Navarro et al. recently employed several elegant assays to explore whether different sets of blood or bone marrow samples produce more accurate results for KIT D816V positivity in SM, with the aim of optimising the test’s sensitivity as well as exploring its potential for prognostics.¹